Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report

Area of Science:

• Neuroscience
• Infectious Diseases
• Pharmacology

Background:

• HIV-associated neurotoxicity is a significant concern.
• Valproic acid (VPA) has shown potential in preclinical models for ameliorating neurotoxicity.
• Existing treatments for HIV-associated neurotoxicity are limited.

Purpose of the Study:

• To evaluate the safety and tolerability of valproic acid (VPA) in HIV-infected individuals.
• To explore the effects of VPA on neuropsychological performance and brain metabolism.
• To assess the potential of VPA as a therapeutic agent for HIV-associated neurotoxicity.

Main Methods:

• A 10-week, randomized, placebo-controlled pilot study.
• Participants: 22 HIV-infected individuals (16 with cognitive impairment, 6 without).
• Intervention: VPA 250 mg twice daily versus placebo.

Main Results:

• VPA was found to be safe and well-tolerated in the study population.
• Trends toward improved neuropsychological performance were observed in subjects with cognitive impairment.
• Preliminary evidence suggests potential improvements in brain metabolism in impaired subjects.

Conclusions:

• Valproic acid (VPA) is a safe and well-tolerated option for HIV-infected individuals.
• VPA demonstrates a promising trend for improving cognitive function and brain metabolism in those with HIV-associated neurotoxicity.
• Further research is warranted to confirm these findings and establish VPA's efficacy.